Open-Label Study Evaluating Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures
Phase of Trial: Phase I/II
Latest Information Update: 22 May 2018
At a glance
- Drugs Cetuximab (Primary)
- Indications Brain cancer
- Focus Diagnostic use
- 12 Jul 2017 Status changed from recruiting to discontinued.
- 06 Dec 2016 Status changed from not yet recruiting to recruiting.
- 12 Oct 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.